Optimised cell culture development for pharma, biotech, CMOs and media providers
Philippe Alexandre Gilbert | Senior Scientist, Cell Culture Development, Research and Development Glaxosmithkline Biologicals Sa
Born in Quebec City (Canada), Dr. Philippe-Alexandre Gilbert is a graduate of the department of biochemistry at the University of Ottawa . He pursued his education at Laval University where he obtained his masters degree in molecular biology and his doctorate in biochemical engineering. For over 14 years now Dr. Gilbert has built a solid expertise in molecular design and development of bioprocesses for gene therapy vectors, oncolytic viruses and vaccines. He had the privilege of working for organizations such as the Biotechnology Research Institute(CNRC), the Robarts Research institute (Western Ontario University), the Emerging Pathogen Institute (University of Florida) and in the private sector with Sanofi-Pasteur, Wellstat Biologics and MedImmune (Astra Zeneca). He has lead task force teams for SARS, HIV, RSV and Pandemic H1N1 Influenza. Dr. Gilbert has recently joined the cell culture department at GSK Biologicals and continues to focus his efforts on new cell culture technology. Dr. Gilbert is the proud father of three children and resides with his family in Belgium.
Share this
Appearances at this years' conference:
Day 3 - Thursday 1st March 2012
@ 10.30
Panel discussion: delivering a robust, yet flexible upstream process
Can the upstream processes become reproducible and efficient by utilising currently available bioreactor technologies?
Highlighting the challenges of process scale-up, and identifying future strategies to deliver a reproducible production cycle
What abilities does the next generation of bioreactor require if the cell culture industry is to continue to grow?
› Philippe Alexandre Gilbert, Senior Scientist, Cell Culture Development, Research and Development, Glaxosmithkline Biologicals Sa
DAY 2 - Wednesday 29th February 2012
@ 16.40
Can single-use bioreactors be implemented in vaccine production?
Evaluating the significant benefits of disposable technologies in this role from reducing investments costs to increasing facility output
Understanding the challenges which need to be overcome due to biosafety, and the need for multiple cell lines increasing the complexity of platform technology
Should viral vaccine production be carried out in disposable technologies or are the association difficulties too great?
› Philippe Alexandre Gilbert, Senior Scientist, Cell Culture Development, Research and Development, Glaxosmithkline Biologicals Sa